Shuttle Pharmaceuticals (SHPH)
Pharmaceutical AI software platform with a planned Dogecoin–Litecoin mining operation.
Something off on this page? Send us feedback.
Develops and plans to license the Molecule.ai pharmaceutical-software platform while building a Scrypt-mining business that merge-mines Dogecoin and Litecoin. Operations are pre-revenue, the oncology program is in wind-down, and the initial mining fleet was awaiting deployment.
Combines Molecule.ai, a modular pharmaceutical-software platform, with United Dogecoin, a newly acquired Scrypt-mining subsidiary. Molecule.ai supports molecular-property prediction, cross-molecule and cross-property evaluation, and structured reasoning; Shuttle intends to use it internally for molecular research and license it to third parties. United Dogecoin is designed to operate owned rigs that merge-mine Dogecoin and Litecoin and retain mined digital assets.
Operates from Gaithersburg, Maryland, with a Canadian Molecule.ai subsidiary and a hosted mining site whose location was not disclosed. The legacy Ropidoxuridine oncology trial is being wound down, while future drug research awaits a decision on direction. Licensing depends on customer adoption, platform performance, security, and stability; mining depends on delivery, installation, hosted power, network conditions, and digital-asset values.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $1.1M · Total debt $214.0K · Total assets $11.8M · Shareholders' equity $3.3M
- Revenue
- $0
- Operating income
- −$2.2M
- Net income
- −$2.2M
No dividends on record.
| Insiders4 holders · as of Mar 21, 2025 | 0.56% | 3.3K shares | |
| Otherremainder | 99.44% | 581.8K shares |
585.1K company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Mira JungInsiderofficer: Chief Scientific Officer | 0.18% | 543 · 536 | Form 4filed Oct 9, 2024 ↗ |
Oleh NabytInsiderdirector | 0.13% | 737 | Form 4filed Mar 21, 2025 ↗ |
George ScorsisInsiderdirector | 0.13% | 737 | Form 4filed Mar 21, 2025 ↗ |
Joseph TungInsiderdirector | 0.13% | 737 | Form 4filed Mar 21, 2025 ↗ |
Armistice Capital, LLCStrategic | —9.99% of class, as filed | — | 13Gfiled May 15, 2025 ↗ |
| See all 20 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 14, 2026 | HRT Financial LP | 10 percent owner | −82,116 | $4.48 |
| Jul 13, 2026 | HRT Financial LP | 10 percent owner | −1,033 | $4.67 |
| Jul 9, 2026 | HRT Financial LP | 10 percent owner | +8,266 | $3.38 |
| Jul 10, 2026 | HRT Financial LP | 10 percent owner | +731 | $3.11 |
| Jul 8, 2026 | HRT Financial LP | 10 percent owner | −18,531 | $3.52 |
- Schrödinger
Hosted molecular-discovery software overlaps with AI modeling licenses.
- Datacentrex
Operating Scrypt mining fleet overlaps directly in DOGE/LTC merge mining.
- Recursion Pharmaceuticals
AI-native drug-discovery platforms target biopharma research programs.
- Absci
Generative-AI biologic design overlaps with AI drug-discovery workflows.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Shuttle Pharmaceuticals | $3.30 | −9.58% | $2.0M | — | — | — | — |
| Schrödinger | $20.72 | −0.77% | $1.56B | — | — | 6.0 | +7.5% |
| Datacentrex | $1.88 | −0.79% | $73.1M | — | — | 6.6 | — |
| Recursion Pharmaceuticals | $3.38 | +0.15% | $1.77B | — | — | 32.3 | −61.8% |
| Absci | $8.83 | +0.29% | $1.49B | — | — | 955.0 | −49.4% |
| Median | — | — | 19.5 | −49.4% |